Topical Finasteride Side Effects: What the Evidence Shows

Medically reviewed by [Reviewer Name, MD] | Last reviewed: August 2026 | Editorial policy

Note: No topical finasteride formulation is FDA-approved in the US as of 2026. All topical use is off-label or compounded. This page covers evidence from clinical trials only.

The theoretical advantage of topical finasteride over oral is reduced systemic exposure, and therefore potentially fewer systemic side effects. Clinical trial data support a more favorable systemic profile, though they do not eliminate systemic side effects entirely.

Side Effect Comparison: Topical vs. Oral

Side Effect	Oral Finasteride 1 mg (Kaufman 1998)	Topical Finasteride 0.25% (Piraccini 2022)
Decreased libido	~1.8%	<1% (comparable to placebo)
Erectile dysfunction	~1.3%	<1%
Ejaculation disorder	~1.2%	<1%
Scalp irritation / contact dermatitis	N/A	~2-4% (vehicle-related)
Serum DHT reduction	~70%	34.5% (oral arm in the same trial: 55.6%)

The lower serum DHT reduction (34.5% vs. 55.6% for oral in Piraccini 2022) is both the mechanism for reduced systemic side effects and a potential trade-off in efficacy. Current evidence suggests topical finasteride is effective but the long-term comparison to oral at matched DHT reduction levels is not fully established.

Local Scalp Reactions

The most common adverse effects specific to topical formulations are local and typically vehicle-related: erythema (redness), pruritus (itching), and dryness at the application site. These are more common with alcohol-based vehicles and typically resolve on their own or with formulation adjustment.